

Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast to 2027

<https://marketpublishers.com/r/MADD06D67919EN.html>

Date: December 2022

Pages: 175

Price: US\$ 4,950.00 (Single User License)

ID: MADD06D67919EN

Abstracts

The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period. Market growth is driven by rise in the number of patients with cancer and hematological malignancies, growing awareness drives regarding cancer by government, and increasing collaborations and partnerships between companies.

“The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period”

The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. Device being easy to use, easy accessibility of assay kits, and a good sensitivity are the major factors contributing the large share of this segment.

“Hematological Malignancies applications segment accounted for the highest CAGR”

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share.

Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.

“Asia Pacific: The fastest-growing region minimal residual disease testing market”

The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.

The Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, the presence of a large pool of patient population, the rising focus of key players in the region, government efforts to increase awareness about the detection of diseases, continuously rising healthcare expenditures, an increasing number of hospitals & clinical diagnostic laboratories in India and China, and the strengthening research base for diagnostic procedures across India, China, and Japan.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%

By Designation: C-level - 30%, D-level - 20%, and Others - 50%

By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, Latin America –9%, and the Middle East & Africa – 3%

Lists of Companies Profiled in the Report:

Labcorp Inc. (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Guardant Health (US)

Sysmex Corporation (Japan)

NeoGenomics Laboratories, Inc. (US)

Adaptive Biotechnologies Corporation (US)

ArcherDX, Inc. (US)

Asuragen Inc. (US)

Arup Laboratories Inc. (US)

Bio-Rad Laboratories, Inc. (US)

Cergentis B.V. (Netherlands)

Molecular MD (ICON plc) (Ireland)

Invivoscribe, Inc. (US)

Mission Bio, Inc. (US)

Natera, Inc. (US)

Opko Health, Inc. (US)

Quest Diagnostics (US)

Genetron Health (China)

Research Coverage:

This report provides a detailed picture of the global minimal residual disease testing market. It aims at estimating the size and future growth potential of the market across different segments, such as technology, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest

approximations of the revenue numbers for the overall minimal residual disease testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 MARKETS COVERED
 - 1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION
 - 1.3.2 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
 - FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
 - 2.2.1 SECONDARY DATA
 - 2.2.1.1 Key data from secondary sources
 - 2.2.2 PRIMARY DATA
 - 2.2.2.1 Primary sources
 - 2.2.2.2 Key data from primary sources
 - 2.2.2.3 Key industry insights
 - 2.2.2.4 Breakdown of primary interviews
 - FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 - FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.3 MARKET SIZE ESTIMATION
 - 2.3.1 BOTTOM-UP APPROACH
 - 2.3.1.1 Approach 1: Company revenue estimation
 - FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 - 2.3.1.2 Approach 2: Presentations of companies and primary interviews
 - 2.3.1.3 Growth forecast
 - 2.3.1.4 CAGR projections

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS**2.3.2 TOP-DOWN APPROACH****FIGURE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH****2.4 MARKET BREAKDOWN AND DATA TRIANGULATION****FIGURE 7 DATA TRIANGULATION METHODOLOGY****2.5 MARKET SHARE****2.6 STUDY ASSUMPTIONS****2.7 GROWTH RATE ASSUMPTIONS****2.8 RISK ASSESSMENT****2.8.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET****3 EXECUTIVE SUMMARY**

FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)

FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)

FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)

FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS**4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW**

FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET

4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027

FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027

4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027

FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2027

4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2022 VS. 2027

FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING

4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Rising incidence of hematological malignancies

TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020

TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030

5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers

5.2.1.3 Increasing cancer awareness initiatives by global health organizations

5.2.2 RESTRAINTS

5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests

5.2.2.2 High cost of minimal residual disease testing kits

5.2.3 OPPORTUNITIES

5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries

TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030

5.2.4 CHALLENGES

5.2.4.1 Unclear reimbursement scenario and policies for patients

5.3 PRICING ANALYSIS

TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022)

5.4 PATENT ANALYSIS

FIGURE 18 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET

5.4.1 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET

5.5 VALUE CHAIN ANALYSIS

FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES

5.6 SUPPLY CHAIN ANALYSIS

FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS

5.7 ECOSYSTEM/MARKET ANALYSIS

FIGURE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM/MARKET ANALYSIS

TABLE 5 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM

5.8 PORTER'S FIVE FORCES ANALYSIS

TABLE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS

5.8.1 THREAT OF NEW ENTRANTS

5.8.2 THREAT OF SUBSTITUTES

5.8.3 BARGAINING POWER OF BUYERS

5.8.4 BARGAINING POWER OF SUPPLIERS

5.8.5 DEGREE OF COMPETITION

5.9 REGULATORY ANALYSIS

TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.9.1 NORTH AMERICA

5.9.1.1 US

5.9.1.2 Canada

5.9.2 EUROPE

5.9.3 ASIA PACIFIC

5.9.3.1 China

TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES

5.9.3.2 Japan

TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA

5.9.4 LATIN AMERICA

5.9.4.1 Brazil

5.9.4.2 Mexico

5.9.5 MIDDLE EAST

5.9.6 AFRICA

5.10 TRADE ANALYSIS

5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS
TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS,
BY COUNTRY, 2017–2021 (USD MILLION)

TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS,
BY COUNTRY, 2017–2021 (USD MILLION)

5.11 TECHNOLOGY ANALYSIS

5.12 KEY CONFERENCES AND EVENTS IN 2022–2023

TABLE 16 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF
CONFERENCES AND EVENTS

5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL
DISEASE TESTING PRODUCT MANUFACTURERS

FIGURE 22 REVENUE SHIFT IN MINIMAL RESIDUAL DISEASE TESTING MARKET

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP
THREE APPLICATIONS

TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL
RESIDUAL DISEASE TESTING PRODUCTS

5.14.2 BUYING CRITERIA

FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING
PRODUCTS

TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING
PRODUCTS

5.15 CASE STUDY ANALYSIS

6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY

6.1 INTRODUCTION

TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)

6.2 POLYMERASE CHAIN REACTION

6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION

TABLE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY
REGION, 2020–2027 (USD MILLION)

6.3 NEXT-GENERATION SEQUENCING

6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET

TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY

REGION, 2020–2027 (USD MILLION)

6.4 FLOW CYTOMETRY

6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH

TABLE 22 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)

6.5 OTHER TECHNOLOGIES

TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION

7.1 INTRODUCTION

TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

7.2 HEMATOLOGICAL MALIGNANCIES

TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020–2027 (USD MILLION)

TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020–2027 (USD MILLION)

7.2.1 LEUKEMIA

TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)

TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)

7.2.1.1 Myeloid leukemia

7.2.1.1.1 High prevalence of AML in adults to support growth

TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)

7.2.1.2 Lymphocytic leukemia

7.2.1.2.1 High incidence of ALL in children to drive market

TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)

7.2.1.3 Other leukemias

TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)

7.2.2 LYMPHOMA

TABLE 32 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)

TABLE 33 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)**7.2.2.1 Non-Hodgkin lymphoma**

7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth

TABLE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)**7.2.2.2 Hodgkin lymphoma**

7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing

TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)**7.3 SOLID TUMORS**

7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH

TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2020–2027 (USD MILLION)**7.4 OTHER APPLICATIONS****TABLE 37 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)****8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER****8.1 INTRODUCTION****TABLE 38 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)****8.2 HOSPITALS & SPECIALTY CLINICS**

8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH

TABLE 39 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2020–2027 (USD MILLION)**8.3 DIAGNOSTIC LABORATORIES**

8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH

TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)**8.4 ACADEMIC & RESEARCH INSTITUTES**

8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET

TABLE 41 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)**8.5 OTHER END USERS**

TABLE 42 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION

9.1 INTRODUCTION

TABLE 43 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)

9.2 NORTH AMERICA

FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

TABLE 44 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 46 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 47 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.2.1 US

9.2.1.1 Increasing prevalence of cancer to drive market

TABLE 48 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 49 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 50 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.2.2 CANADA

9.2.2.1 Availability of various cancer screening programs to support market growth

TABLE 51 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 52 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 53 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.3 EUROPE

TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020–2035

TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 56 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 57 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 58 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.3.1 GERMANY

9.3.1.1 Government support for research funding to support MRD testing market

TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020

TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 61 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 62 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.3.2 UK

9.3.2.1 Increasing number of diagnostic laboratories to propel market growth

TABLE 63 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 64 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 65 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.3.3 FRANCE

9.3.3.1 Rising R&D expenditure in France to drive market

TABLE 66 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 67 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 68 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.3.4 ITALY

9.3.4.1 Favorable funding scenario to drive market

TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020

TABLE 70 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 71 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 72 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,

2020–2027 (USD MILLION)

9.3.5 SPAIN

9.3.5.1 Consolidation of laboratories in Spain to support market growth

TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 74 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 75 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.3.6 REST OF EUROPE

TABLE 76 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 77 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 78 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.4 ASIA PACIFIC

FIGURE 26 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

TABLE 79 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 80 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 81 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 82 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.4.1 CHINA

9.4.1.1 Growing public access to advanced healthcare facilities to drive market

TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020

TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 85 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 86 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.4.2 JAPAN

9.4.2.1 Universal healthcare reimbursement policy to support market growth

TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020

TABLE 88 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 89 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 90 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.4.3 INDIA

9.4.3.1 Increasing private and public investments in healthcare system to drive market

TABLE 91 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 92 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 93 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.4.4 REST OF ASIA PACIFIC

TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019

TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 96 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 97 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.5 LATIN AMERICA

9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET

TABLE 98 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 99 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 100 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.6 MIDDLE EAST & AFRICA

9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET

TABLE 101 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 102 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 103 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN

10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET

TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET

10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS

FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET

10.4 MARKET SHARE ANALYSIS

FIGURE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER (2021)

TABLE 105 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION

10.5 COMPANY EVALUATION QUADRANT

10.5.1 LIST OF EVALUATED VENDORS

10.5.2 STARS

10.5.3 EMERGING LEADERS

10.5.4 PERVASIVE PLAYERS

10.5.5 PARTICIPANTS

FIGURE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021

10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)

10.6.1 PROGRESSIVE COMPANIES

10.6.2 STARTING BLOCKS

10.6.3 RESPONSIVE COMPANIES

10.6.4 DYNAMIC COMPANIES

FIGURE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021

10.7 COMPETITIVE BENCHMARKING

10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS

FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS

TABLE 106 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGIONAL FOOTPRINT OF COMPANIES

TABLE 107 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES

TABLE 108 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES**10.8 COMPETITIVE SCENARIO****10.8.1 PRODUCT LAUNCHES****TABLE 109 KEY PRODUCT LAUNCHES****10.8.2 DEALS****TABLE 110 KEY DEALS****11 COMPANY PROFILES****11.1 KEY PLAYERS**

(Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)*

11.1.1 ADAPTIVE BIOTECHNOLOGIES**TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW****FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)****11.1.2 ARCHERDX (INVITAE CORPORATION)****TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW****FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021)****11.1.3 ASURAGEN, INC.****TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW****11.1.4 BIO-RAD LABORATORIES, INC.****TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW****FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)****11.1.5 F. HOFFMANN-LA ROCHE AG****TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW****FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)****11.1.6 GUARDANT HEALTH, INC.****TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW****FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)****11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)****TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW****FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021)****11.1.8 INVIVOSCRIBE, INC.****TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW****11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS****TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW**

FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)

11.1.10 NATERA, INC.

TABLE 120 NATERA, INC.: BUSINESS OVERVIEW

FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021)

11.1.11 SYSMEX CORPORATION

TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW

FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)

11.2 OTHER PLAYERS

11.2.1 NEOGENOMICS LABORATORIES

11.2.2 OPKO HEALTH, INC.

11.2.3 GENETRON HEALTH

11.2.4 QUEST DIAGNOSTICS, INC.

11.2.5 ARUP LABORATORIES INC.

11.2.6 MISSION BIO, INC.

11.2.7 CERGENTIS B.V.

*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.

12 APPENDIX

12.1 DISCUSSION GUIDE

12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

12.3 CUSTOMIZATION OPTIONS

12.4 RELATED REPORTS

12.5 AUTHOR DETAILS

I would like to order

Product name: Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast to 2027

Product link: <https://marketpublishers.com/r/MADD06D67919EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MADD06D67919EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970